Link to this page
Biological and Environmental Research Ontology
| Id | http://purl.obolibrary.org/obo/NCIT_C114500
http://purl.obolibrary.org/obo/NCIT_C114500
|
|---|---|
| Preferred Name | Enfortumab Vedotin |
| Definitions |
An antibody drug conjugate (ADC) containing a human monoclonal antibody AGS-22 targeting the cell adhesion molecule nectin-4 and conjugated to the cytotoxic agent monomethyl auristatin E (MMAE), via a proprietary enzyme-cleavable linker (AGS-22CE), with potential antineoplastic activity. The monoclonal antibody moiety of enfortumab vedotin selectively binds to nectin-4. After internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces apoptosis in nectin-4 overexpressing tumor cells. Nectin-4, a tumor associated antigen belonging to the nectin family, is overexpressed in a variety of cancers, including breast, bladder, lung and pancreatic cancer.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An antibody drug conjugate (ADC) containing a human monoclonal antibody AGS-22 targeting the cell adhesion molecule nectin-4 and conjugated to the cytotoxic agent monomethyl auristatin E (MMAE), via a proprietary enzyme-cleavable linker (AGS-22CE), with potential antineoplastic activity. The monoclonal antibody moiety of enfortumab vedotin selectively binds to nectin-4. After internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces apoptosis in nectin-4 overexpressing tumor cells. Nectin-4, a tumor associated antigen belonging to the nectin family, is overexpressed in a variety of cancers, including breast, bladder, lung and pancreatic cancer. |
|---|---|
| prefLabel | Enfortumab Vedotin
|
| label | Enfortumab Vedotin
|
| NCI_META_CUI | CL472325
|
| PDQ_Closed_Trial_Search_ID | 759429
|
| code | C114500
|
| prefixIRI | NCIT:C114500
|
| in_subset | |
| Preferred_Name | Enfortumab Vedotin
|
| FDA_UNII_Code | DLE8519RWM
|
| Contributing_Source | FDA
|
| Maps_To |
Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E
Enfortumab Vedotin
|
| CAS_Registry | 1346452-25-2
|
| NCI_Drug_Dictionary_ID | 759429
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 759429
|
| Accepted_Therapeutic_Use_For | adult patients with locally advanced or metastatic urothelial cancer (mUC) who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.
|
| Semantic_Type | Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |